Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Activating EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02769286
What this trial is testing

Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA

Who this might be right for
Lung NeoplasmsEGFR Gene Mutations
Chonnam National University Hospital 38
Large-scale testing (Phase 3)UnknownNCT03074864
What this trial is testing

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

Who this might be right for
Non-small Cell Lung CancerEpidermal Growth Factor Receptor
Guangdong Provincial People's Hospital 90
Testing effectiveness (Phase 2)Looking for participantsNCT05948813
What this trial is testing

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Who this might be right for
NSCLCEGFR Activating MutationBrain Metastases
TYK Medicines, Inc 420
Testing effectiveness (Phase 2)UnknownNCT02930954
What this trial is testing

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Who this might be right for
Non-small-cell Lung Cancer
Caicun Zhou 180
Testing effectiveness (Phase 2)Ended earlyNCT02500927
What this trial is testing

ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Who this might be right for
EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Astellas Pharma Inc 31
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Testing effectiveness (Phase 2)UnknownNCT02319577
What this trial is testing

GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial

Who this might be right for
Non Small Cell Lung Cancer
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy 80
Testing effectiveness (Phase 2)Study completedNCT01897480
What this trial is testing

LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 168
Testing effectiveness (Phase 2)Study completedNCT05039177
What this trial is testing

ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Who this might be right for
Metastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma
Erasca, Inc. 101
Not applicableEnded earlyNCT02483416
What this trial is testing

Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 30
Testing effectiveness (Phase 2)Study completedNCT00525148
What this trial is testing

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 129
Testing effectiveness (Phase 2)Study completedNCT01469000
What this trial is testing

Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non Small Cell Lung
Eli Lilly and Company 195
Testing effectiveness (Phase 2)Study completedNCT02264210
What this trial is testing

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Who this might be right for
Lung NeoplasmsSquamous Cell Lung CancerAdenocarcinoma of the Lung+4 more
Sun Yat-sen University 128
Not applicableUnknownNCT01776684
What this trial is testing

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Who this might be right for
EGFR Mutation Positive Non-small Cell Lung Cancer
Samsung Medical Center 200
Testing effectiveness (Phase 2)WithdrawnNCT03042013
What this trial is testing

Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Who this might be right for
Subjects With NSCLC With an EGFR Activating Mutation
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07699952
What this trial is testing

First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

Who this might be right for
Lung Cancer (NSCLC)EGFR Activating MutationHER2
Yongsheng Wang 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT05463224
What this trial is testing

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

Who this might be right for
NSCLC
Sehhoon Park 150
Testing effectiveness (Phase 2)Study completedNCT01833572
What this trial is testing

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Who this might be right for
Non-small-cell Lung Cancer
Fudan University 36
Large-scale testing (Phase 3)Study completedNCT02759614
What this trial is testing

Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

Who this might be right for
NSCLC
Guangdong Association of Clinical Trials 311
Testing effectiveness (Phase 2)Study completedNCT00411047
What this trial is testing

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Massachusetts General Hospital 34
Next Page